Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation versus withdrawal of sitagliptin during insulin glargine initiation in type 2 diabetes
2015-004990-34Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in HbA1c at Week 30 and Event rate of documented symptomatic hypoglycemia with blood glucose less than or equal to 70 mg/dL over 30 weeks. Started Apr 2016; status: completed.
02
Drugs
sitagliptininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-004990-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004990-34.